Agios Pharmaceuticals, Inc.
AGIO
Updated: 24/09/2026, 06:56:15
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
No summaries found.
- Share price
- $34.19
- Market cap
- $2.04B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Brian Goff
- Employees
- 540
- IPO date
- 24/07/2013
- Beta
- 0.6
- Last dividend
- $0.00
- Day range
- $34.09 – $34.87
- 52-week range
- $22.24 – $46.00
- 1-day performance
- -2.23%
- 1-year performance
- 53.73%
- Current drawdown (1Y)
- -25.67%
- CIK
- 0001439222
- CUSIP
- 00847X104
- ISIN
- US00847X1046
- Created
- 07/12/2025, 01:58:16
- Last update
- 24/09/2026, 06:56:15
Track Agios Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move AGIO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
MarketBeat • STOCK • 13/06/2026, 16:07:19
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
Seeking Alpha • STOCK • 13/06/2026, 16:02:09
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
GlobeNewsWire • STOCK • 13/06/2026, 11:00:00
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Zacks Investment Research • STOCK • 02/06/2026, 13:25:17
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Seeking Alpha • STOCK • 01/06/2026, 18:24:07
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Zacks Investment Research • STOCK • 29/05/2026, 14:32:12
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
GlobeNewsWire • STOCK • 29/05/2026, 09:00:00
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
Zacks Investment Research • STOCK • 25/05/2026, 14:11:06
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
GlobeNewsWire • STOCK • 22/05/2026, 11:15:00
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Zacks Investment Research • STOCK • 13/05/2026, 14:25:37
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
GlobeNewsWire • STOCK • 12/05/2026, 11:31:00
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
GlobeNewsWire • STOCK • 12/05/2026, 11:30:00